Sree N. Pattipati, MPharm, PhD

Associate Dean, College of Biosciences and Health Professions
Interim VP of Research
Professor
559-369-2713
spattipati@chsu.edu

Degrees:

PhD in Neuropsychopharmacology, Faculty of Pharmaceutical Sciences, Panjab University, India

MPharm in General Pharmacology, Panjab University, India

BS in Pharmaceutical Sciences, Kakatiya University, India

Professional Specialty:

General Pharmacology, Neuropharmacology and Psychopharmacology

Most recent experience:

Associate Dean and Professor, Master of Science in Biomedical Sciences, CHSU

Adjunct Professor, California State University, Fresno, CA

Research interests:

Cannabinoids; Affective and Neurodegenerative Disorders; Pain and inflammation; Fibrotic Disorders

Most recent publications and presentations:

Guanglin Luo, Ling Chen, Walter A Kostich, Brian Hamman, Jason Allen, Amy Easton, Clotilde Bourin, Michael Gulianello, Jonathan Lippy, Susheel Nara, Sreenivasulu Naidu Pattipati et al. Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain. Journal of Medicinal Chemistry 2022; 65 (6), 4534-4564

Guanglin Luo, Ling Chen, Walter A. Kostich, Brian Hamman, Jason Allen, Amy Easton, Clotilde Bourin, Michael Gulianello, Jonathan Lippy, Susheel Nara, Tarun Kumar Maishal, Kamalraj Thiyagarajan, Prasadrao Jalagam, Sreenivasulu Naidu Pattipati et al., Discovery of (S)-1-((2′,6-Bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry 2022; 65 (6), 4457-4480

Srikumar BN, Sreenivasulu Naidu Pattipati et al., Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus. Journal of psychopharmacology 2019; 33(1): 25-36.

Marcin LR, Warrier J, Thangathirupathy S, Shi J, Karageorge GN, Pearce BC, Ng A, Park H, Kempson J, Li J, Zhang H, Mathur A, Reddy AB, Nagaraju G, Tonukunuru G, Gupta GVRKM, Kamble M, Mannori R, Cheruku S, Jogi S, Gulia J, Bastia T, Sanmathi C, Aher J, Kallem R, Srikumar BN, Vijaya kumar K, Sreenivasulu Naidu Pattipati et al., BMS-986163, a Negative Allosteric Modulator of  GluN2B  with  Potential  Utility  in  Major  Depressive  Disorder.  ACS   Med.   Chem.  Lett., 2018, 9 (5),  472–477

Bristow LJ, Guli J, Weed MR, Srikumar BN, Li Y-W, Graef JD, Sreenivasulu Naidu Pattipati et al., Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4- methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-D- Aspartate 2B (GluN2B) Receptor Negative Allosteric Modulator with Potential in Treatment Resistant  Depression.  Journal  of   Pharmacology   and   Experimental   Therapeutics  2017, 363 (3) 377-393.

Find more publications on Pubmed